DK2442647T3 - Dithiolforbindelser, derivater deraf og anvendelser af disse - Google Patents

Dithiolforbindelser, derivater deraf og anvendelser af disse Download PDF

Info

Publication number
DK2442647T3
DK2442647T3 DK10790038.3T DK10790038T DK2442647T3 DK 2442647 T3 DK2442647 T3 DK 2442647T3 DK 10790038 T DK10790038 T DK 10790038T DK 2442647 T3 DK2442647 T3 DK 2442647T3
Authority
DK
Denmark
Prior art keywords
lens
compound
agents
pharmaceutically acceptable
age
Prior art date
Application number
DK10790038.3T
Other languages
English (en)
Inventor
William Garner
Margaret Garner
George Minno
David Gooden
Original Assignee
Encore Health Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Health Llc filed Critical Encore Health Llc
Application granted granted Critical
Publication of DK2442647T3 publication Critical patent/DK2442647T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (7)

1. Forbindelse eller et farmaceutisk acceptabelt salt deraf, med strukturen:
hvor Z' er en hvilken som helst farmaceutisk acceptabel modion, til anvendelse ved behandling af gammelsynethed.
2. Forbindelse til anvendelse ifølge krav 1, hvor Z' er et sulfat, methansulfo-nat, nitrat, maleat, acetat, citrat, fumarat, tartrat, succinat, benzoat, glutamat, chlorid, bromid eller iodid.
3. Forbindelse til anvendelse ifølge krav 2, som er
4. Farmaceutisk sammensætning omfattende en forbindelse med strukturen:
hvor Z- er en hvilken som helst farmaceutisk acceptabel modion; og et farmaceutisk acceptabelt hjælpestof.
5. Farmaceutisk sammensætning ifølge krav 4, hvor Z' er et sulfat, methan-sulfonat, nitrat, maleat, acetat, citrat, fumarat, tartrat, succinat, benzoat, glutamat, chlorid, bromid eller iodid.
6. Farmaceutisk sammensætning ifølge krav 4, hvor forbindelsen er
7. Farmaceutisk sammensætning ifølge et af kravene 4 til 6, hvor den farmaceutiske sammensætning er formuleret til okulær anvendelse.
DK10790038.3T 2009-06-15 2010-06-15 Dithiolforbindelser, derivater deraf og anvendelser af disse DK2442647T3 (da)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US18700509P 2009-06-15 2009-06-15
US18694009P 2009-06-15 2009-06-15
US18703909P 2009-06-15 2009-06-15
US18701809P 2009-06-15 2009-06-15
US18702309P 2009-06-15 2009-06-15
US18702809P 2009-06-15 2009-06-15
US18698609P 2009-06-15 2009-06-15
US18703309P 2009-06-15 2009-06-15
US22493009P 2009-07-13 2009-07-13
US23505109P 2009-08-19 2009-08-19
US23791209P 2009-08-28 2009-08-28
US24223209P 2009-09-14 2009-09-14
PCT/US2010/038632 WO2010147957A2 (en) 2009-06-15 2010-06-15 Dithiol compounds, derivatives, and uses therefor

Publications (1)

Publication Number Publication Date
DK2442647T3 true DK2442647T3 (da) 2016-05-30

Family

ID=43357007

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10790038.3T DK2442647T3 (da) 2009-06-15 2010-06-15 Dithiolforbindelser, derivater deraf og anvendelser af disse

Country Status (5)

Country Link
US (4) US8795706B2 (da)
EP (4) EP2442647B1 (da)
DK (1) DK2442647T3 (da)
PL (1) PL2442647T3 (da)
WO (1) WO2010147957A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
PT2442645E (pt) 2009-06-15 2014-11-05 Encore Health Llc Ésteres de colina
PL2442647T3 (pl) 2009-06-15 2016-09-30 Związki ditiolowe, pochodne i ich zastosowania
DK2640423T3 (da) * 2010-11-18 2017-10-02 Ischemix Llc Lipoylforbindelser og deres anvendelse til behandling af iskæmisk skade
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
TWI600418B (zh) 2012-10-17 2017-10-01 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
JP6480340B2 (ja) 2012-11-15 2019-03-06 ブランデイズ ユニバーシティー 環状ジスルフィドを用いるシステイン残基のテザリング
BR112016020181A8 (pt) 2014-03-03 2021-06-29 Encore Vision Inc composições de ácido lipoico éster colina e métodos de uso.
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) * 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
US10449209B2 (en) 2015-04-29 2019-10-22 Arterez, Llc Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
RU2724955C2 (ru) * 2015-05-21 2020-06-29 Офтэлмис Монако Офтальмологическая композиция, содержащая липоевую кислоту и мукомиметический полимер
CA2994298A1 (en) 2015-08-18 2017-02-23 Brandeis University Tethering cysteine residues using cyclic disulfides
US10844038B2 (en) 2016-09-08 2020-11-24 Sabila Biosciences Llc 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
EP3615023B1 (en) 2017-04-25 2023-06-21 Ischemix LLC Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN108586429A (zh) * 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法
CN108822077A (zh) * 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法
EP3900728A4 (en) 2018-12-18 2022-08-17 Santen Pharmaceutical Co., Ltd. AGENT CONTAINING URSODESOXYCHOLIC ACID FOR TREATING OR PREVENTING PRESBYOPIA
WO2020129965A1 (ja) 2018-12-18 2020-06-25 参天製薬株式会社 ４－フェニル酪酸を含有する老視の治療または予防剤
EP3957365A4 (en) * 2019-04-17 2023-01-11 Santen Pharmaceutical Co., Ltd. LIPOIC ACID PRODRUG
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
JPWO2021241582A1 (da) 2020-05-26 2021-12-02
KR20230042077A (ko) * 2020-09-11 2023-03-27 인트라투스-네바다, 인크. 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法
WO2024059754A1 (en) * 2022-09-14 2024-03-21 Quantapore, Inc. Polythiolated linkers for stable nanoparticle suspensions and uses thereof
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1043604A (en) 1911-04-05 1912-11-05 Julius Orwan Clothes-line hanger.
GB935962A (en) * 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3387008A (en) 1965-06-28 1968-06-04 Eastman Kodak Co Process for making a substantially ester free fatty acid alkanolamide product
US3855240A (en) * 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) * 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
JPH0732323B2 (ja) 1989-05-30 1995-04-10 住友金属鉱山株式会社 共振周波数の温度係数を調整可能な共振器
WO1993002639A1 (en) * 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4633793A (en) 1992-06-10 1994-01-04 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
EP0648118A1 (en) * 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6313274B1 (en) 1992-07-06 2001-11-06 Thomas R. Sykes Photoactivation of proteins for conjugation purposes
US5465737A (en) * 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
US5354331A (en) * 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
JPH08500035A (ja) * 1992-08-07 1996-01-09 ケラビジョン，インコーポレイテッド 角膜実質内ハイブリッドリング
DE4345199C2 (de) * 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) * 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) * 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
WO1996002663A1 (en) 1994-07-18 1996-02-01 Gist-Brocades B.V. PROCESS FOR PREPARATION OF β-LACTAMS AT CONSTANTLY HIGH CONCENTRATION OF REACTANTS
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
EP0939628B1 (en) * 1996-07-22 2003-03-05 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6007510A (en) * 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US5843184A (en) * 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) * 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
EP1133317A1 (de) * 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
WO2000074672A1 (en) * 1999-06-09 2000-12-14 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
CA2417842A1 (en) * 2000-08-02 2003-01-30 Basf Aktiengesellschaft Method for producing lipoic acid and dihydrolipoic acid
US6923955B2 (en) * 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
WO2002013863A2 (en) 2000-08-16 2002-02-21 Refocus, Llc. Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
DE10045059A1 (de) * 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
JP2005506096A (ja) 2001-01-19 2005-03-03 ニューレンズ、エルエルシー 水晶体の変化による老眼治療
ATE446949T1 (de) * 2001-03-19 2009-11-15 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
CA2448062A1 (en) * 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2003084532A1 (en) 2002-04-03 2003-10-16 Avery Mitchell A Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
CN100367949C (zh) * 2002-09-13 2008-02-13 有限会社绪方研究 黑色素消除制剂
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
AU2004293477A1 (en) 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) * 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
AU2006270035A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US20070055070A1 (en) * 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
CA2691775A1 (en) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
GB2459809A (en) * 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
UA86441C2 (ru) 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
PL2442647T3 (pl) 2009-06-15 2016-09-30 Związki ditiolowe, pochodne i ich zastosowania
PT2442645E (pt) * 2009-06-15 2014-11-05 Encore Health Llc Ésteres de colina

Also Published As

Publication number Publication date
EP3069612A3 (en) 2016-10-19
US8795706B2 (en) 2014-08-05
EP3542629A3 (en) 2020-01-01
US9567314B2 (en) 2017-02-14
US20170231951A1 (en) 2017-08-17
US20160264545A1 (en) 2016-09-15
US20100317608A1 (en) 2010-12-16
US9284305B2 (en) 2016-03-15
EP3069612A2 (en) 2016-09-21
WO2010147957A2 (en) 2010-12-23
US10039743B2 (en) 2018-08-07
WO2010147957A3 (en) 2011-03-03
PL2442647T3 (pl) 2016-09-30
US20150246903A9 (en) 2015-09-03
US20140357691A1 (en) 2014-12-04
EP2442647A2 (en) 2012-04-25
EP3542629A2 (en) 2019-09-25
EP2442647A4 (en) 2012-09-19
EP2442647B1 (en) 2016-03-16
EP4082542A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
DK2442647T3 (da) Dithiolforbindelser, derivater deraf og anvendelser af disse
DK2821405T3 (da) Cholinestere til behandling af presbyopi og katarakt
US8647612B2 (en) Dithiol compounds, derivatives, and treatment of presbyopia
DK2364084T3 (da) Farmaceutiske sammensætninger med lavdosis liponsyre og fremgangsmåder
WO2009111635A2 (en) Dithiol compounds, derivatives, and uses therefor
DE69704833T2 (de) Derivate der thiazolidine-4-carbonsäure als cytoprotektive mittel
ESTERS PATENT APPLICATION
TW202330510A (zh) 對老花眼等之治療或預防有用之含硫化合物